The Food and Drug Administration Friday released for comment through Dec. 13 a discussion paper on certain novel drug manufacturing technologies with the potential to increase timely access to drugs. 

“Pharmaceutical manufacturers have generally produced drugs at large fixed-location facilities, but some are now developing smaller, mobile drug manufacturing processes that can be deployed to multiple locations, including at the point of care, such as at a hospital or clinic,” FDA said. “These novel distributed manufacturing (DM) and point-of-care (POC) manufacturing technologies have the potential to improve the reliability and robustness of the drug supply chain.”

Related News Articles

Headline
The AHA Jan. 5 filed its opening brief in its lawsuit challenging a December 2022 rule issued by the Department of Health and Human Services’ Office for Civil…
Headline
The Food and Drug Administration will accept nominations through Dec. 11 for experts to serve on a committee that will advise the agency on issues related…
Headline
Hear how Northwestern Medicine is using digital technology to better prepare teams to work in the new world of health care, and why a digital mindset is vital…
Headline
The Kaiser Family Foundation has released a tool to help monitor changes in Medicaid enrollment as states redetermine eligibility due to the end of the…
Headline
The Department of Health and Human Services' Office of the National Coordinator for Health Information Technology today released a proposed rule that…
Headline
The International Hospital Federation’s Geneva Sustainability Centre seeks hospitals to preview and provide feedback on a digital platform it plans to launch…